Clinical and metabolic effects associated with weight changes and obeticholic acid in non‐alcoholic steatohepatitis
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Summary: Background: In a 72‐week, randomised controlled trial of obeticholic acid (OCA) in non‐alcoholic steatohepatitis (NASH), OCA was superior to placebo in improving serum ALT levels and liver histology. OCA therapy also reduced weight. Aims: Because weight loss by itself can improve histology, to perform a post hoc analysis of the effects of weight loss and OCA treatment in improving clinical and metabolic features of NASH. Methods: The analysis was limited to the 200 patients with baseline and end‐of‐treatment liver biopsies. Weight loss was defined as a relative decline from baseline of 2% or more at treatment end. Results: Weight loss occurred in 44% (45/102) of OCA and 32% (31/98) of placebo‐treated patients (P = 0.08). The NAFLD Activity score (NAS) improved more in those with than without weight loss in both the OCA‐ (−2.4 vs −1.2, P<0.001) and placebo‐treated patients (−1.2 vs −0.5, P = 0.03). ALT levels also improved in those with vs without weight loss in OCA‐ (−43 vs −34 U/L, P = 0.12) and placebo‐treated patients (−29 vs −10 U/L, P = 0.02). However, among those who lost weight, OCA was associated with opposite effects from placebo on changes in alkaline phosphatase (+21 vs −12 U/L, P<0.001), total (+13 vs −14 mg/dL, P = 0.02) and LDL cholesterol (+18 vs −12 mg/dL, P = 0.01), and HbA1c (+0.1 vs −0.4%, P = 0.01). Conclusions: OCA leads to weight loss in up to 44% of patients with NASH, and OCA therapy and weight loss have additive benefits on serum aminotransferases and histology. However, favourable effects of weight loss on alkaline phosphatase, lipids and blood glucose seen in placebo‐treated patients were absent or reversed on OCA treatment. These findings stress the importance of assessing concomitant metabolic effects of new therapies of NASH. Clinical trial number: NCT 01265498.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Self-citationSingh, S., Allen, A. M., Wang, Z., Prokop, L. J., Murad, M. H., & Loomba, R. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.04.014 · Cited by 1,748
Self-citationRole of Bile Acids and Bile Acid Receptors in Metabolic Regulation
Lefebvre, P., Cariou, B., Lien, F., Kuipers, F., & Staels, B. (2009) · Physiological Reviews · doi:10.1152/physrev.00010.2008 · Cited by 1,678
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
Nevens, F., Andreone, P., Mazzella, G., Strasser, S. I., Bowlus, C., Invernizzi, P., Drenth, J. P. H., Pockros, P. J., Regula, J., Beuers, U., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509840 · Cited by 1,131 · cited 2×
“Weight loss with OCA therapy has not been reported in treatment studies of patients with primary biliary cholangitis.(19) The mechanism underlying this weight loss in patients with NASH is unknown but FXR TABLE 2 (Continued)”
BackgroundResultMudaliar, S., Henry, R. R., Sanyal, A. J., Morrow, L., Marschall, H., Kipnes, M., Adorini, L., Sciacca, C. I., Clopton, P., Castelloe, E., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.05.042 · Cited by 931 · cited 1×
“In animal models of NAFLD, OCA decreased hepatic fat and fibrosis(11,12) and in a pilot randomised, placebo-controlled trial in patients with type II diabetes, OCA improved insulin sensitivity and was associated with a decrease in serum alanine aminotransferase (ALT) and c-glutamyl transpeptidase levels in those with…”
MethodKim, D., Kim, R. W., Kim, H. J., & Therneau, T. M. (2013) · Hepatology · doi:10.1002/hep.26156 · Cited by 772
Verbeke, L., Farre, R., Trebicka, J., Komuta, M., Roskams, T., Klein, S., Elst, I. V., Windmolders, P., Vanuytsel, T., Nevens, F., et al. (2014) · Hepatology · doi:10.1002/hep.26939 · Cited by 258
Research works printed but not linked: 15
- 10.1002/hep.28431 · DOI · Paper page
- 10.1016/j.jpeds.2012.08.043 · DOI · Paper page
- 10.1053/j.gastro.2014.11.039 · DOI · Paper page
- 10.1002/hep.27678 · DOI · Paper page
- 10.2337/db13-0299 · DOI
- 10.1074/jbc.M510258200 · DOI · Paper page
- 10.1021/jm049904b · DOI · Paper page
- 10.1194/jlr.M001602 · DOI · Paper page
- 10.1111/apt.12352 · DOI · Paper page
- 10.1002/hep.20701 · DOI · Paper page
- 10.1007/BF03085956 · DOI
- 10.1016/S0895-4356(00)00314-0 · DOI · Paper page
- 10.1194/jlr.R024794 · DOI · Paper page
- 10.1161/ATVBAHA.109.197897 · DOI · Paper page
- 10.1111/j.1365-2036.2008.03752.x · DOI
Cited by
Molecular physiology of bile acid signaling in health, disease, and aging
Perino, A., Demagny, H., Velazquez-Villegas, L., & Schoonjans, K. (2021) · Physiological Reviews · doi:10.1152/physrev.00049.2019 · Cited by 481
Nonalcoholic Fatty Liver Disease and the Heart
Stahl, E. P., Dhindsa, D. S., Lee, S. K., Sandesara, P. B., Chalasani, N. P., & Sperling, L. S. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.050 · Cited by 439
Self-citationBile acids and their receptors in metabolic disorders
Fiorucci, S., Distrutti, E., Carino, A., Zampella, A., & Biagioli, M. (2021) · Progress in Lipid Research · doi:10.1016/j.plipres.2021.101094 · Cited by 258
Nonalcoholic fatty liver disease in adults: current concepts in etiology, outcomes, and management
Marjot, T., Moolla, A., Cobbold, J. F., Hodson, L., & Tomlinson, J. W. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz009 · Cited by 228
Factors associated with histologic response in adult patients with nonalcoholic steatohepatitis
Loomba, R., Sanyal, A. J., Kowdley, K. V., Terrault, N., Chalasani, N. P., Abdelmalek, M. F., McCullough, A. J., Shringarpure, R., Ferguson, B., Lee, L., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.09.021 · Cited by 124
Self-citation
Metadata
- Authors
- Hameed, B., Terrault, N. A., Gill, R. M., Loomba, R., Chalasani, N., Hoofnagle, J. H., Van Natta, M. L., & CRN, F. T. N.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2018-01-14
- Volume
- 47
- Issue
- 5
- Pages
- 645-656
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W2782978792
- Cited by
- 73
- References
- 7
- FWCI
- 7.33
- Type
- journal article
- Language
- en
- Open access
- bronze
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (U01DK061718, U01DK061728, U01DK061731, U01DK061732, U01DK061734, U01DK061737, U01DK061738, U01DK061730, U01DK061713)
- National Center for Advancing Translational Sciences (UL1TR000439, UL1TR000436, UL1TR000006, UL1TR000448, UL1TR000100, UL1TR000004, UL1TR000423, UL1TR000058)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.